- Lobbying
- Lobbying by Boehringer & Ingelheim Pharmaceuticals
Lobbying Relationship
Bills mentioned
H.R.1: American Recovery and Reinvestment Act of 2009
Sponsor: David R. Obey (D-Wis.)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Thomas Scully | Administrator, Consultant, CMS; Counselor to the Dir., Dep. Ass't to the Pres., Dir. for Hum. Res. Vet's & Lab., Assoc. Dir. for Leg. Affairs, OMB |
Mark Rayder | Leg. Ass't, Rep. T. Latham; Leg. Ass't Rep. R. Frelinghuysen District Rep., Rep. D. Gallo |
Colin Roskey | Health Pol. Adv'r and Counsel, Sen. Fin. Comm. |
Marilyn Yager | Dep. Ass't to the Pres., White House Office of Public Liason |
Jennifer Bell | Health Pol. Adv'r, Sen Fin Comm; Leg. Ass't, Sen. J. Thune |
Rudy Missmar | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate